Global Institute Of Stem Cell Therapy And Research
US: +1-800-914-7836

What's new

Latest news

Honourable Speaker Dr Anand Srivastava at 1st International Conference on Medicine and Research (ICMR-21)

1st International Conference on Medicine and Research (ICMR-21)

Topic : Role of Stem Cell in Covid-19

Dr. Srivastava is a Chairman and Cofounder of the California-based Global Institute of
Stem Cell Therapy and Research (GIOSTAR) headquartered in San Diego, California
(USA). Several governments and organizations – including the United States, India,
China, Turkey, Kuwait, Thailand, Philippines, Bahamas, Saudi Arabia and many others

  • seek his advice and guidance on drafting their strategic and national policy
    formulations and program directions in the area of stem cell research, development,
    and its regulations.

The company was formed with the vision to provide stem cell based therapy to aid
those suffering from degenerative or genetic diseases around the world such as
Parkinson’s disease, Alzheimer’s disease, neuropathy, diabetes, heart disease, stroke,
spinal cord injuries, paralysis, and blood related diseases. GIOSTAR is a leader in
developing the most advanced stem cell based technology, supported by leading
scientists with pioneering publications in the area of stem cell biology. The company’s
primary focus is to discover and develop a cure for human diseases, with state-of-theart,
unique stem cell based therapies and products. Regenerative medicine provides
promise for treatments of diseases previously regarded as incurable.

Under Dr. Srivastava’s creative leadership, a group of esteemed scientists and
clinicians are developing stem cell therapies for various types of autoimmune diseases
and blood disorders.

Dr. Anand Srivastava has been associated with leading universities and research
institutions throughout the world. In affiliation with University of California San Diego
(UCSD) School of Medicine, University of California Irvine (UCI) School of Medicine,
The Salk Institute for Biological Studies in San Diego, The Sanford Burnham Prebys
Medical Discovery Institute, and University of California, Los Angeles (UCLA) School of
Medicine, Dr. Srivastava has developed several research projects. He has extensive
research experience in the field of stem cells, which is documented by several
publications in revered scientific journals.

California, United States
Dr. ANAND Srivastava, MS,

Click here to Download the PDF : ICMR-21

Cure being Medicine’s Holy Grail, Stem Cell Major GIOSTAR beacons Article by Medicare News

The Leading Indian American Company unveils in Bangalore to script amazing treatment outcomes

Bangalore/ New Delhi: With Indian American Stem Cell Major GIOSTAR-USA arriving in a mission mode to alleviate the sufferings and pain of sick people, words ‘Cure’ and ‘Anti-ageing’ are in Indian air. Its elegant hospital unveiled in Bangalore only this month has set the stage for India to witness amazing outcomes of stem cell therapy.

Headquartered in San Diego, California and powered by two illustrious Indians, Dr Anand Srivastava and Deven Patel, GIOSTAR (Global Institute of Stem Cell Research) with 20 plus years in the field is a cut above the rest among stem cell research and therapy players in the world. The hospital was inaugurated by Gurudev Sri Sri Ravishankar on October 17, 2021, equating stem cell scientists as versions of Brahma for their power to regenerate damaged organs.

Sample this: In a world first, in April 2020, FDA (Food & Drug Administration) in USA gave emergency use authorization to GIOSTAR for using stem cell therapy for repairing damaged lungs from COVID infection which proved lifesaving at a time when vaccine was not there and treatment protocol seemed like stabbing in the dark. It is one of the first stem cell research institutes to achieve this distinction in USA. It is a great measure of GIOSTAR’s credibility and speaks a volume about GIOSTAR’s standing in the realm of stem cell research and therapy (also named regenerative medicine).

Talking to Medicare News, Dr Anand Srivastava, Chairman of GIOSTAR and a globally acclaimed preeminent stem cell scientist elaborated on treatment of COVID patients and said ‘We wrote to FDA for emergency use authorization claiming we could save people who were dying due to COVID- damaged lungs. Thankfully, we got it and saved several people, making headlines in America in the midst of killing spree of the pandemic. We wanted to save people in India as well and so spoke to Indian regulators but our words fell on deaf ears.’

If cure is the holy grail of medicine, GIOSTAR’s quest is catching up fast. In mainstream medicine, ailments are only managed with lifelong need to take medicines. Complete cure of ailments is what makes drugless and non- invasive stem cell therapy a very attractive proposition. With GIOSTAR going whole hog into creating stem cells banks and doing clinical trials in right earnest, the patients despairing to rid of terminal illnesses may soon start seeing light at the end of dark tunnel in India.

GIOSTAR, which already has amazing treatment success stories to flaunt, is all set to bring a paradigm shift in the way the treatments are delivered in India. If you take Dr Anand Srivastava’s deep and unlimited devotion to Hanuman, the much-revered Hindu God, you might as well say he is endowed with ‘Sanjivani’ for hapless patients on the verge of death. Stem Cell therapy promises to regenerate and repair kidney, heart, liver, eyes, brain, and what not. Thanks to Stem cells, Kidney and Liver transplant, knee replacement and many other procedures of treatment might be thing of the past in times to come.

Dr Srivastava adds- ‘Healing at the cellular level is the real treatment resulting into complete cure. GIOSTAR is well equipped to script such cures. Stem cell therapy is no more in the nascent experimental stage. It has come of age and it is high time to harness stem cell products to treat illnesses so far regarded incurable. It is very much possible now to treat with felicity stroke, traumatic brain injuries, Autism, Parkinson, Alzheimer, multiple sclerosis, glaucoma, cerebral palsy, myocardial infraction, diabetes, autoimmune disease like Crohn’s disease, liver diseases.’

Dr Srivastava has many laurels and firsts to his credit, well documented in prestigious medical journals, namely, making universal (O-negative) blood in 2003 by stem cells, proving for the first time ever in 2005 that brain damage could be repaired with stem cells, to name but a few. The clinical trials being taken up by GIOSTAR in Bangalore and in America may open a new exciting chapter in Medicine.

Talking to Medicare News, Deven Patel, President, CEO & Cofounder, said, ‘GIOSTAR’s mission is to facilitate affordable stem cell therapy to the masses. The company is all set to herald an age when people will go to chemist shop to get a vial of stem cell product over the counter to get it infused in body like we do with glucose. And lo and behold! you recover without using any drug and resultant side effects. We are pioneers in stem cell science. Anti- ageing, which is most sought-after dream of all and sundry, is GIOSTARS’s hard earned craft and I am the living example of it.’

Deven Patel said the company is going to establish GIOSTAR hospitals in every metropolis of India. He further added GIOSTAR, a much sought-after stem cell institutes, will be in every continent as well in very near future. Mr Patel added GIOSTAR is going to begin clinical trials on stem cells applications. The clinical trial areas are Post COVID complications, diabetes, auto immune diseases, Cancer, Vaccine Alzheimer and most important of all, the universal donor O-(negative)Blood that GIOSTAR has created with the help of stem cells.

America has achieved stem cell science superiority by spending billions of dollars with the help of chosen stem cell scientists. Dr Anand Srivastava is one of them and regarded as pioneer and power house of Stem Cell knowledge. According to Deven Patel, India can have those accomplishments of USA just for an asking and can assume leadership role. Thankfully, GIOSTAR has got the ears of PM Narendra Modi. It is to be noted that GIOSTAR hospital in Ahmedabad was inaugurated by PM Modi when he was CM of Gujrat in 2011 and MOU was signed in 2009 in Vibrant Gujrat. Gurudev Sri Sri Ravishankar also graced the occasion that time.  With GIOSTAR as partner, a huge stem cell hospital is in the making in Surat on the line of PPP model and several states have signed MOU with GIOSTAR for similar projects to establish most advanced stem cell research and treatment institutes for better health of millions in India.

Summing up, it might take some time for stem cell therapy to become mainstream medicine but the huge potential of stem cells is a fait accompli. Alarmed, pharmaceutical companies have buying stem cell companies to monopolise it.

Top 10 Influential Entrepreneurs in Healthcare 2021

Top 10 Influential Entrepreneurs in Healthcare 2021

GIOSTAR is a San Diego, California-based organization led by Dr. Anand Srivastava and Deven Patel. Dr. Srivastava has held scientific positions at leading universities and research institutions in the United States, such as the University of California Irvine and UC Los Angeles, along with the following San Diego-based institutions: Salk Institute for Biological Studies, Sanford Burnham Prebys Medical Discovery Institute. He has authored more than 100 scientific publications, and is widely regarded as the “father of stem cell science.” Under his leadership, GIOSTAR has been one of the pioneers in the field of stem cell therapy. Few in the scientific community were willing to accept the therapeutic efficacy of stem cells, despite the publication of numerous studies providing supporting evidence. In contrast to these skeptics, GIOSTAR joined the leading groups of scientists and researchers in embracing the science and sought to build upon its compendium of findings.

GIOSTAR’s vision is to provide its scientific and medical expertise to establish the most advanced stem cell therapy and research institutes around the world. The company actively seeks public and private sector investors to help deliver stem cell-based therapies to people suffering from degenerative or genetic diseases. GIOSTAR is in the process of expanding its operations in the US, India, China, Thailand, Philippines, Japan, Australia, Singapore, Brazil, Bahamas, and a few more countries.

What were the constraints you faced at the time of inception?

GIOSTAR faced several ethical and financial constraints at the inception of the company, and for a few years thereafter. As the primary findings in the field were based on embryonic stem cells, social and ethical groups vehemently opposed the use of stem cells for research and therapy. These objections culminated in restrictions on fundings from government agencies. However, scientists demonstrated that stem cells could be isolated from adult tissues, paving the way for extensive research and the application of the science for therapeutic purposes. Since most of the therapeutic interventions in conventional medicine are palliative (i.e., they only help manage symptoms), it was difficult for people to accept that any therapy could be curative, a capability uniquely afforded by stem cells.

What unique services do you provide to the customers?

GIOSTAR has several unique characteristics that distinguish us from our peers. Our Institute has been the pioneer in the research field of stem cell science, with a firm commitment to staying abreast of the latest developments with this technology. Second, we want to offer our patients comprehensive therapeutic help, which is thoroughly tested in our numerous clinics. Finally, our services are rooted in an altruistic, humanitarian mission to help the masses, as opposed to an opportunistic quest to derive monetary gain from patients’ suffering.

Why should one prefer you?

GIOSTAR delivers therapies that are customized to each patient’s health conditions, grounded in decades of logical, scientific research. We evaluate the body as a cohesive unit, as opposed to a disjointed collection of organs and ailments. This holistic perspective enables us to devise and deliver the most effective therapies.

What personality traits and capabilities do you believe are required to enhance and promote health solution providing services?

Certain characteristics are essential for success in any field. Healthcare, in particular, requires that its practitioners possess an unyielding dedication to the well-being of all humans. GIOSTAR takes this commitment very seriously and approaches healthcare in a highly integrated manner, as opposed to the traditional compartmentalized perspective. This practice, coupled with the use of stem cells, enables us to devise the most effective therapies to manage the myriad of health problems of our patients. Share about your journey from the beginning. Our professional journey began with the recognition of the potential for stem cells to serve as a highly effective therapeutic agent for treating several degenerative diseases. In beginning, our firm had to overcome a great deal of skepticism about the efficacy of this GIOSTAR Influential Entrepreneurs in Healthcare, Top 10 2021 Dr. Anand Srivastava Chairman & Co-founder technology. However, scientists and those in the general community alike began expressing great enthusiasm after experiencing the therapeutic wonders of science first-hand. This led to GIOSTAR and other leading stem cell institutions receiving steadily increasing recognition.

How do you manage the promotion of your project through social media outreach and email campaigns?

GIOSTAR relies primarily on word-of-mouth referrals to augment our patient base. After they experience dramatic positive results following the treatments in our global facilities, patients frequently refer friends, family members, and other loved ones to GIOSTAR. Given our impressive success rate, they feel that our firm is uniquely positioned to provide therapeutic benefit to those suffering from the most debilitating disorders.

What do you think about the expansion of GIOSTAR? What will be the plan?

At present, our clinics are in India and Mexico. We are in negotiations with business groups for further expansion in Japan, Thailand, South Africa, and several other countries.

How do you see the future of healthcare in nearby times?

A thorough re-evaluation of our medical system is needed, on numerous fronts: Financial. The cost of training medical professionals is increasing exponentially every year, which may result in a severe shortage of well-trained medical professionals. Coupled with the exorbitant investments required for developing new therapeutic agents, effective medical care will likely become cost prohibitive for most patients. Holistic Approach. Currently, healthcare in the United States is focused primarily on interventions that “buy some time” for the body to heal; in other words, not many interventions are truly curative. Therapies are currently geared toward specific diseases and treat organs as individual, disconnected compartments of the body. Because of this narrow focus, modern medicine has been ineffective in treating metabolic diseases. Healthcare professionals should instead view the entire body as a unit, and devise therapies accordingly; this approach will pave the way for cures for metabolic diseases. As we know, cells are the unit of life and stem cells are the master cells. Hence, these cells are aptly suited to repair damaged organs in a very holistic manner. In our scientific view, stem cells are the least expensive and the best way to manage several metabolic diseases.

Can you describe emerging trends you noticed HEALTHCARE industry?

The most significant change we’ve observed in healthcare is the super specialization of medical professionals. The side effects of the trend of superspecialization are adversely affecting the availability of health care personnel as so super-specialized persons may be fewer and fewer. Additionally, the extensive investment of time and money into super-specialized training will likely dissuade intelligent, capable individuals from entering the health care profession. In addition, clinicians are inclining more towards the holistic approach to managing a metabolic disease and not treating a disease just blocking a signaling pathway which often comes up with several side effects.

Please tell us if there is an effective solution to the current COVID-19 scenario? Coronavirus, which causes COVID-19, induces severe inflammation and lung damage. This can be effectively managed by using a specific category of stem cells known as mesenchymal stem cells (MSCs). These cells are well-known for their capabilities for immunomodulatory function and tissue regeneration, thus providing a two-pronged approach for battling COVID-19. Therefore, MSCs provide the best clinical option for managing COVID-19 symptoms and related organ damage. Based on these facts, GIOSTAR procured approval from the United States Food and Drug Administration (FDA) for using stem cells for COVID-19 patients under the FDA “expanded access for compassionate use” program. The company was then able to successfully treat patients who were gravely ill with the disease.

  • Year of Founding : 2008
  • Funding Information : Mostly research grants.
  • Founding Members : Dr. Anand Srivastava and Mr. Deven Patel
  • Office Locations : 4660 La Jolla Village Drive Suite 100 & 200 San Diego, California, 92122, U.S.A. (headquarters)
  • Company Strength: Varies between 25-70.
  • Website :
  • News Link :


GIOSTAR Launches Subsidiary to Combat COVID-19 and Long COVID

Stem cell research institute seeks to ramp up the charge against global pandemic

SAN DIEGO, May 5, 2021 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in regenerative technologies, is pleased to announce the formation of GIOCOV. The company – launched in tandem with TAG Investment Bankers LTD of London (TAG) – is a wholly-owned subsidiary aimed at delivering stem cell-based treatments for the acute phase of COVID-19, along with the chronic phase (known as Long COVID).

A Long Haul for Millions

As of May 2021, roughly 280 million individuals have been fully vaccinated against COVID-19. The worldwide rollout has helped contain the impact and reduce the high morbidity rates of the disease – which has claimed more than 3 million lives. However, data reveals that, even after recovering from COVID-19, many patients continue experiencing a compendium of debilitating symptoms known collectively as Long COVID.

These “long-haulers” may experience one or both of the following:

  • Symptoms experienced throughout the course of COVID-19: fatigue, cognitive impairment (brain fog), difficulty breathing, headaches, difficulty exercising, depression, sleep difficulty, loss of sense of taste or smell
  • New symptoms: hair loss, anxiety, and heart problems

In a study conducted by the Centers for Disease Control (CDC), roughly 1 in 3 patients (including both mild and severe cases) observed suffered from highly debilitating symptoms of COVID-19 several weeks after their diagnosis. Even more alarming, a University of Leicester investigation found that 7 in 10 patients hospitalized for COVID-19 didn’t fully recover 5 months after discharge. These grim statistics point to a dire global health crisis, with enormous projected costs of management.

“Long COVID is very serious,” noted World Health Organization (WHO) Director-General Tedros Adhanom Ghebreyesus. “To a significant number of people, this virus poses a range of serious long-term effects. The symptoms people have to endure are very debilitating, leading many to be unable to work and function properly.” Long COVID issues may ultimately culminate in chronic disease, requiring sharply increased levels of medication, long-term hospitalization, and debilitating lifestyle changes that will likely lead to premature death.

Extending the Impact of Novel Therapeutic Approach

GIOSTAR has played a central role in the fight against COVID-19. The US Food and Drug Administration (FDA) granted the firm FDA Approval Under Compassionate Use (Expanded Access Program) to treat COVID-19 patients – making GIOSTAR one of the first companies in the world to obtain this credential. Leveraging proprietary scientific protocols and techniques developed by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR succeeded in treating several critically ill COVID patients using stem cells.

“The anti-inflammatory capabilities of stem cells make them an excellent therapeutic agent,” explained Dr. Srivastava. “Further, their ability to differentiate into myriad cells helps to restore organ function, thereby enabling [patient] recovery from the post-COVID-19 syndrome.”

GIOSTAR is looking to build upon its success in addressing the acute phase of COVID-19. With the launch of GIOCOV, the company is now pursuing the fully licensed status of stem cell treatment for COVID and Long COVID patients in the United States (US), United Kingdom (UK), and the European Union (EU). This goal will require completion of clinical trials to establish treatment protocols and secure full approval from FDA, Medicines and Healthcare products Regulatory Agency (MHRA), and European Medicines Agency (EMA) – the regulatory bodies for the US, UK, and EU respectively. Upon receiving this, GIOCOV seeks to gain acceptance from healthcare authorities, providers, and insurers alike for reimbursement of treatment costs.

“GIOCOV’s aim is to provide cost-effective treatment for all Long COVID sufferers worldwide,” noted GIOSTAR CEO and Co-Founder Deven Patel. “This will show huge cost-benefit against the cost of long-term medication and hospitalization and provide enhanced quality of life to patients all over the globe.” Given the results of the aforementioned study, more than 100 million long-haulers (representing 70% of the over 150 million total COVID 19 cases) stand to achieve enormous economic and health-related benefits from this initiative.

To realize these goals GIOSTAR – in collaboration with their advisors TAG Investment Bankers Ltd of London – intends for GIOCOV to raise funds to carry out the necessary trials through a listing on the London Stock Exchange (LSE), Nasdaq, and other stock exchanges. GIOSTAR also aims to secure funding from suitable grants.

GIOSTAR is pleased to officially announce its pre-IPO fundraising round, the details of which are available at the TAG Investment Bankers Website:


GIOSTAR is the pioneer and established leader in the field of stem cell science and regenerative medicine. Based in San Diego, California, USA, the company’s primary aim is to develop treatments for the masses suffering from metabolic and degenerative diseases around the globe.

GIOSTAR is a coalition of world-class scientists, physicians, and entrepreneurs in the field of stem cell science. The team members have been involved for the last 20 years in the development and utilization of stem cell-based clinical protocols related to degenerative, malignant, and non-malignant disorders. The adult stem cell technology is well developed and has been used regularly in the Institute’s clinical practice to treat many patients.

Media Contact

Chris Paget
COO at TAG Investment Bankers Ltd
Tel: +44 7801 413597

Related Links

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

Promising results point to a potential alternative in combating the pandemic

SAN DIEGO, July 21, 2020 /PRNewswire/ — Global Institute of Stem Cell Therapy and Research (GIOSTAR), the worldwide leader in stem cell research, is pleased to announce the outcome of a COVID-19 patient treated using stem cells. Led by Chairman and Co-Founder Dr. Anand Srivastava, GIOSTAR received approval for the treatment under the U.S. Food and Drug Administration (FDA) “expanded access for compassionate use” program. As of July 14, 2020, there have been more than 13 million COVID-19 cases and over 500,000 deaths worldwide.

Contending with a Grim Prognosis

Under the direction of GIOSTAR Medical Director Dr. Prabhat Soni, a 53-year old male patient suffering from COVID-19 pneumonia was admitted to Saint Michael’s Medical Center in Newark, New Jersey, under the care of Dr. Richard Miller, MD, Chairman, Department of Pulmonary Medicine. The patient’s condition worsened over the course of the standard treatments, along with convalescent plasma therapy. He went into septic shock and his renal and hepatic functions continued to decline, requiring dialysis. The patient suffered a stroke, and remained in a coma at Saint Michael’s intensive care unit (ICU).

GIOSTAR Reports on a Positive Outcome of a COVID-19 Patient After Stem Cell Treatment

Improved Outcomes from an Alternative Strategy

Noting the limited effectiveness of these measures, Dr. Soni designed a plan to treat the patient using stem cells. Research physician Dr. Michael J. DeMarco coordinated the plan, with day-to-day care provided to the patient by Dr. Miller and his Critical Care fellows Dr. Rutwik Patel and Dr. Harish Sharma, at Saint Michael’s.

Following treatment with AlloRx Stem Cells® from Vitro Biopharma, a Colorado-based company, the patient began recovery from multiple organ failure and a coma of almost 7 weeks.  He had excellent recovery of his pulmonary, liver, and renal functions, ultimately coming off dialysis and ventilator support.

The patient’s recovery of neuro-muscular functions is evident in improved clarity of speech, ease of swallowing food, and many other everyday functions. Additionally, the elevated levels of inflammation markers seen prior to stem cell therapy have come down to within normal range. The patient was finally discharged from ICU, and is undergoing physical therapy with strong hopes of complete recovery.

COVID-19 and Mesenchymal Stem Cells (MSCs)

COVID-19 infection leads to uncontrolled release of proinflammatory cytokines – known as “cytokine storms” – that potentially leads to fatal damage of many organs of the body. “MSCs have specific characteristics that, when infused in the bloodstream,” explained Dr. Srivastava, “neutralize proinflammatory cytokines (through ‘immunomodulation’), down-regulate the inflammatory gene actions and send messages to regenerate damaged lung and other tissues, which may help in managing COVID-19.”

Next Steps for Treatment of COVID-19

“We got outstanding results after using MSCs on our first patient,” noted Dr. Soni, “with similar results being reported by other institutions.” Dr. Srivastava states that “the use of MSCs may be a great option not only for critically ill COVID-19 patients, but also for those who may have risk of exposure. MSCs may prevent people from aggravations of the infection, thereby potentially saving lives while lowering the load on hospitals and the economy.” Drs. Srivastava and Soni emphasize that a placebo-controlled, double-blind study would be needed to better understand the measurable outcome of stem cell treatment for COVID-19.


GIOSTAR is the pioneer and established leader in the field of stem cell research. Under the leadership of Co-Founders Dr. Anand Srivastava and Mr. Deven Patel, the San Diego-based Institute has a tradition of groundbreaking research in stem cell science spanning over two decades.

 Media contact

Deven Patel

Related Links

Make An Inquiry

We are here to help you

WordPress Video Lightbox